Attune Medical of Chicago, IL at MEDICA 2017 in Düsseldorf -- MEDICA Trade Fair

Attune Medical

3440 S. Dearborn St. # 215-S, 60616 Chicago, IL
United States of America

Telephone +1 888 5344873
Fax +1 888 4814756
info@attune-medical.com

This company is co-exhibitor of
Messe Düsseldorf North America

Hall map

MEDICA 2017 hall map (Hall 16): stand E10-8

Fairground map

MEDICA 2017 fairground map: Hall 16

Contact

Markus Toedtling

Phone
+43 660 432 0185

Email
mtoedtling@attune-medical.com

Our range of products

Product categories

  • 01  Electromedical equipment / Medical Technology
  • 01.03  Therapie and physical medicine
  • 01.03.16  Thermotherapy systems

Thermotherapy systems

Our products

Product category: Thermotherapy systems

EnsoETM

Attune’s initial product, the EnsoETM (formerly Esophageal Cooling Device or ECD), is designed to modulate and control patient temperature through a single-use, fully-enclosed system that is inserted into the esophagus. Two lumens attach to an external heat exchange unit while a third, independent, lumen simultaneously allows gastric decompression and drainage. The EnsoETM can be rapidly placed by most trained healthcare professionals, in similar fashion to a standard gastric tube, and can be used to control patient temperature in the operating room, recovery room, emergency room, and/or intensive care unit. No other products on the market are approved to use the esophageal environment for whole-body temperature modulation.

More Less

Company news

Date

Topic

Download

Oct 20, 2017

Clinical Study Published in Resuscitation Demonstrates Efficacy and Safety of Attune Medical’s EnsoETM for Cooling and Rewarming Patients

The COOL Study is largest prospective study evaluating esophageal temperature management to date

CHICAGO--(BUSINESS WIRE)--A clinical study published in the journal Resuscitation has demonstrated the efficacy and safety of Attune Medical’s EnsoETM in cooling and rewarming patients after out-of-hospital cardiac arrest (OHCA). The article, “Targeted Temperature Management Using The Esophageal Cooling Device After Cardiac Arrest (The COOL Study)”, assessed the performance and safety of the EnsoETM (previously named the Esophageal Cooling Device, or ECD) during a Targeted Temperature Management (TTM) protocol.

TTM is a therapeutic protocol that is associated with improved outcomes in patients successfully resuscitated after OHCA. The therapy is optimized by reaching and strictly maintaining a target temperature between 32-36°C for 24 hours, then slowly rewarming at a controlled rate to return to normal body temperature. In this study, all 17 patients reached 34°C and the device demonstrated an “excellent ability” to accurately maintain target temperature (on average within 0.1°C), and to rewarm at a controlled rate of 0.2°C/hr. Endoscopic evaluations to assess EnsoETM safety found no injuries attributable to the device. The authors note that other temperature management methods, such as endovascular or intraperitoneal cooling, can be expensive and invasive with a higher rate of side-effects.

Study highlights:

All patients (100%) reached the target temperature range.
The cooling rate was similar to invasive technologies previously evaluated by the institution.
Goal temperature maintenance was superior to the best advanced cooling devices.
No adverse effects were caused by the device.
The study authors comment that the ETM could be “an interesting device to implement a 36°C protocol, because this internal device seems very efficient to correctly maintain the target temperature without the need for supplemental devices generating potential complications.”

Senior author of the article, Dr. Nicolas Deye, Researcher in Medicine and Toxicology who specializes in the field of cardiac arrest in the Intensive Care Unit of Lariboisiere University Hospital, Inserm U-942, Paris, France, commented, "The ECD is an interesting new tool to safely and easily provide precise targeted temperature management after cardiac arrest, using an alternative and semi-invasive approach."

Dr. Erik Kulstad, Attune’s CEO, Founder and inventor of the EnsoETM, remarked, “This study further validates the use of esophageal temperature management as a simple, safe and effective approach to control patient temperature, both for cooling or warming. Accurate targeted temperature management is becoming increasingly vital in a wide range of conditions, and the EnsoETM provides a clinically differentiated, cost effective solution to meet the needs of clinicians.”

Formerly known as Advanced Cooling Therapy, Attune Medical’s proprietary technology simplifies access to the patient’s core to efficiently control core temperature, whether warming or cooling. Attune Medical’s primary device, the EnsoETM (formerly Esophageal Cooling Device or ECD), is designed to modulate and control patient temperature through a single-use, fully-enclosed system that is inserted into the esophagus. Two lumens attach to an external heat exchange unit while a third, independent, lumen simultaneously allows gastric decompression and drainage. The EnsoETM can be rapidly placed by most trained healthcare professionals, in similar fashion to a standard gastric tube, and can be used to control patient temperature in the operating room, recovery room, emergency room, or intensive care unit. No other products on the market are approved to use the esophageal environment for whole-body temperature modulation.

Attune Medical (as Advanced Cooling Therapy) received US FDA de novo clearance for the EnsoETM (Esophageal Cooling Device or ECD) in 2015 for use with the Medi-Therm III by Stryker®. It received FDA 510(k) clearance in 2016 for use with the Blanketrol® II and III Hyper-Hypothermia systems made by Cincinnati Sub-Zero, a Gentherm Company, and FDA 510(k) clearance for use with the Altrix System by Stryker® in 2017. It received its CE Mark in Europe in 2014, with an expanded indication for use up to 120 hours in 2016 and a CE Mark for use with the Altrix System by Stryker® in 2017. It is also licensed for sale in Canada and Australia.

More Less

Oct 20, 2017

Attune Medical Closes $10 Million Series C Financing To Support Continued Global Adoption of Esophageal Temperature Management Device


CHICAGO--(BUSINESS WIRE)--Chicago-based medical device firm Attune Medical has closed a $10 million Series C financing with participation from existing investors, several associates, and new investors. Attune will use the fundraise to support continued revenue growth in the North American market and expansion across key markets worldwide of its EnsoETM esophageal temperature management product line. The EnsoETM is the only patient temperature management system approved for use in the esophageal environment for whole-body temperature modulation, including both warming and/or cooling.

“Being located in Minnesota, one of the more significant medical device hubs in the world, our investment team reviews many device investment opportunities,“ commented David Russick, Founder of Gopher Angels. ”
The Series C Financing features continued participation by existing investors such as the Gopher Angels, the Heartland Angels, and TWB Investment Partners, along with many Attune Medical associates. New investors include the PFG Group, plus several other private investors.

“Being located in Minnesota, one of the more significant medical device hubs in the world, our investment team reviews many device investment opportunities,“ commented David Russick, Founder of Gopher Angels.

Paul Hansen, former President of 3M Mexico, and member of Gopher Angels, notes “We are investing significantly in Attune Medical for the third time based on the strength of the company’s continued overall market uptake, increasing use on a per-hospital basis, and accelerating expansion into warming applications in the OR for longer, more involved cases when patient warming is a challenge. We are proud to continue to support Attune Medical's groundbreaking work in improving temperature control for patients.“

John Schreiner, a member of the TWB Investment Partnership and the Perkins Coie attorney who represented Attune in the financing, commented, “Attune Medical’s EnsoETM is shifting the paradigm in targeted temperature management solutions in the healthcare space. This simple, cost-effective and safe platform represents a new, and we think better, option for clinicians who need to cool or warm patients.”

Attune Medical’s Chief Operating Officer, Keith Warner, commented, “This funding from investors sends a strong statement with respect to their confidence in Attune’s success as well as our opportunity for continued growth. Attune’s proven product requires no additional capital equipment purchase, and we are pleased to report continued adoption by a growing number of major hospitals in the U.S. and around the world.”

Formerly known as Advanced Cooling Therapy, Attune Medical has developed proprietary medical device technology that simplifies access to the patient’s core to efficiently control core temperature. Whether warming or cooling, the company optimizes, or “tunes,” patient temperature safely and effectively. Attune’s initial product, the EnsoETM (formerly Esophageal Cooling Device or ECD), is designed to modulate and control patient temperature through a single-use, fully-enclosed system that is inserted into the esophagus. Two lumens attach to an external heat exchange unit while a third, independent, lumen simultaneously allows gastric decompression and drainage. The EnsoETM can be rapidly placed by most trained healthcare professionals, in similar fashion to a standard gastric tube, and can be used to control patient temperature in the operating room, recovery room, emergency room, and/or intensive care unit. No other products on the market are approved to use the esophageal environment for whole-body temperature modulation.

Attune Medical (as Advanced Cooling Therapy) received US FDA de novo clearance for the EnsoETM (Esophageal Cooling Device or ECD) in 2015 for use with the Medi-Therm III by Stryker®. The company received FDA 510(k) clearance in 2016 for use with the Blanketrol® II and III Hyper-Hypothermia systems made by Cincinnati Sub-Zero, a Gentherm Company, and FDA 510(k) clearance for use with the Altrix System by Stryker® in 2017. It received its CE Mark in Europe in 2014, with an expanded indication for use up to 120 hours in 2016 and a CE Mark for use with the Altrix System by Stryker® in 2017. It is also licensed for sale in Canada and Australia.

More Less